First Wave BioPharma's (NASDAQ: FWBI) Exclusive License: Repurposing Capeserod for GIT Disorder Solutions
First Wave BioPharma (NASDAQ: FWBI) experienced an impressive pre-market surge of approximately 85% on Thursday following the announcement of a licensing agreement with Sanofi (NASDAQ: SNY) concerning Capeserod, a potential treatment for gastrointestinal tract (GIT) disorders. The Agreement: According to the terms of the agreement, the biotech company based in Boca Raton, Florida, will obtain